General features of anti-TIF1γ patients with and without anti-Sp4 autoantibodies
| Anti-Sp4+ (n=26) | Anti-Sp4− (n=35) | P value | Total (N=61) | |
| Female sex | 81% (21) | 89% (31) | 0.5 | 85% (52) |
| Race | ||||
| White | 85% (22) | 86% (30) | 1.0 | 85% (52) |
| Black | 0% (0) | 11% (4) | 0.1 | 7% (4) |
| Other races | 15% (4) | 3% (1) | 0.2 | 8% (5) |
| Age of onset (years) | 43.0 (13.8) | 50.6 (15.3) | 0.05 | 47.4 (15.1) |
| Time of follow-up (years) | 7.1 (4.3) | 4.8 (2.7) | 0.01 | 5.8 (3.7) |
| Number of visits per participant | 10.2 (7.7) | 10.9 (6.7) | 0.7 | 10.6 (7.1) |
| Cancer-associated myositis | 0% (0) | 14% (5) | 0.04 | 8% (5) |
| Death during follow-up | 0% (0) | 9% (3) | 0.3 | 5% (3) |
| Anti-Ro52 | 15% (4) | 17% (6) | 1.0 | 16% (10) |
| Treatments | ||||
| Corticosteroids | 81% (21) | 71% (25) | 0.4 | 75% (46) |
| Azathioprine | 27% (7) | 29% (10) | 0.9 | 28% (17) |
| Methotrexate | 62% (16) | 54% (19) | 0.6 | 57% (35) |
| Mycophenolate | 46% (12) | 46% (16) | 1.0 | 46% (28) |
| Intravenous immunoglobulin | 38% (10) | 57% (20) | 0.1 | 49% (30) |
| Rituximab | 12% (3) | 17% (6) | 0.7 | 15% (9) |
Dichotomous variables were expressed as percentage (count) and continuous variables as mean (SD). Bivariate comparisons of continuous variables were made using Student’s t-test, while bivariate comparisons of dichotomous variables were made either using χ2 test or Fisher’s exact test, as appropriate.